Serum syndecan-1 concentration in hospitalized patients with heart failure may predict readmission-free survival

• DOI: 10.1371/journal.pone.0260350
• Publication Date: 2021-12-08T18:35:17Z
• Authors: Yuichiro Kitagawa; Itta Kawamura; Keiko Suzuki; Hideshi Okada; Takuma Ishihara; Hiroyuki Tomita; Kodai Suzuki; Chihiro Takada; So Sampei; Soichiro Kano; Kohei Kondo; Hirotaka Asano; Yugo Wakayama; Ryo Kamidani; Yuki Kawasaki; Hirotsugu Fukuda; Ayane Nishio; Takahito Miyake; Tetsuya Fukuta; Ryu Yasuda; Hideaki Oiwa; Yoshinori Kakino; Nagisa Miyazaki; Takatomo Watanabe; Takahiro Yoshida; Tomoaki Doi; Akio Suzuki; Shozo Yoshida; Hitoshi Matsuo; Shinji Ogura
• Keywords: Syndecan 1; Glycocalyx; Univariate analysis

Syndecan-1 is found in the endothelial glycocalyx and released into bloodstream during stressed conditions, including severe diseases such as acute kidney injury, chronic disease, cardiovascular disease. This study investigated prognostic value of serum syndecan-1 concentration patients with heart failure upon admission. Serum was analyzed 152 who were hospitalized for worsening from September 2017 to June 2018. The primary outcome readmission-free survival, defined time first admission readmission worsened or death any cause, which assessed at 30 months after discharge hospital. secondary survival time. Blood samples echocardiogram data analyzed. Univariate multivariable time-dependent Cox regression analyses adjusted age, creatinine levels, use antibiotics conducted. significantly associated survival. Subsequently, may have gradually decreased treatment. administration human atrial natriuretic peptide modified relationship between (p = 0.01 0.008, respectively). concentrations, indicate injury glycocalyx, predict failure.